Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Genocea Biosciences (NASDAQ:GNCA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.
Profitability
This table compares Adaptimmune Therapeutics and Genocea Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptimmune Therapeutics | -25.43% | -74.15% | -15.09% |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
Institutional & Insider Ownership
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptimmune Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Adaptimmune Therapeutics currently has a consensus price target of $2.79, suggesting a potential upside of 323.57%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptimmune Therapeutics is more favorable than Genocea Biosciences.
Earnings and Valuation
This table compares Adaptimmune Therapeutics and Genocea Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptimmune Therapeutics | $60.28 million | 2.79 | -$113.87 million | ($0.22) | -2.99 |
| Genocea Biosciences | $1.91 million | 0.00 | -$33.20 million | ($0.61) | N/A |
Genocea Biosciences has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Summary
Adaptimmune Therapeutics beats Genocea Biosciences on 10 of the 13 factors compared between the two stocks.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
